Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
API SUPPLIERS
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
KDMF
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
KDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
87
PharmaCompass offers a list of Pranlukast Hydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Pranlukast Hydrate manufacturer or Pranlukast Hydrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pranlukast Hydrate manufacturer or Pranlukast Hydrate supplier.
A Pranlukast Hemihydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pranlukast Hemihydrate, including repackagers and relabelers. The FDA regulates Pranlukast Hemihydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pranlukast Hemihydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pranlukast Hemihydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Pranlukast Hemihydrate supplier is an individual or a company that provides Pranlukast Hemihydrate active pharmaceutical ingredient (API) or Pranlukast Hemihydrate finished formulations upon request. The Pranlukast Hemihydrate suppliers may include Pranlukast Hemihydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Pranlukast Hemihydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Pranlukast Hemihydrate Drug Master File in Japan (Pranlukast Hemihydrate JDMF) empowers Pranlukast Hemihydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Pranlukast Hemihydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Pranlukast Hemihydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Pranlukast Hemihydrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pranlukast Hemihydrate Drug Master File in Korea (Pranlukast Hemihydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pranlukast Hemihydrate. The MFDS reviews the Pranlukast Hemihydrate KDMF as part of the drug registration process and uses the information provided in the Pranlukast Hemihydrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pranlukast Hemihydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pranlukast Hemihydrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pranlukast Hemihydrate suppliers with KDMF on PharmaCompass.
Pranlukast Hemihydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pranlukast Hemihydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Pranlukast Hemihydrate GMP manufacturer or Pranlukast Hemihydrate GMP API supplier for your needs.
A Pranlukast Hemihydrate CoA (Certificate of Analysis) is a formal document that attests to Pranlukast Hemihydrate's compliance with Pranlukast Hemihydrate specifications and serves as a tool for batch-level quality control.
Pranlukast Hemihydrate CoA mostly includes findings from lab analyses of a specific batch. For each Pranlukast Hemihydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pranlukast Hemihydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Pranlukast Hemihydrate EP), Pranlukast Hemihydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pranlukast Hemihydrate USP).
